The Future of Cannabidiol (CBD) in Big Pharma's Shadow

If big pharma’s attempt to take over the hemp or CBD space is inevitable, then CBD may be in the endgame. CBD’s endgame is a crucial time for companies learning to adapt and succeed in this next wave of pharma-like regulatory fury. Success in the next wave requires a true sense of urgency in forming partnerships between scientists, clinicians, government/regulators, industry, and patients. Together, these teams can develop the strategic roadmap required for success, whether it be in large-scale evidence-based clinical trials or in the next blockbuster OTC or wellness product. A strategic roadmap that leverages safety and science can lead to critical policy changes and improved health outcomes

Despite the growing interest of CBD in society, it is clear that many health professionals, scientists, physicians, and the government were not prepared for the huge explosion of CBD use. Historically, the few scientists and clinicians interested in studying CBD, even 10 years ago, faced regulatory roadblocks owing to its current and confusing status as a schedule 1 drug. As such, there are today (01/20/18) only approximately 21 published clinical studies investigating CBD as a standalone drug (as opposed to in combination with Δ9-tetrahydrocannabinol (THC), such as Sativex).

CBD companies have been lucky so far, a virtual draught of new medications to treat mental health issues has led to increased use of CBD for mental health issues, such anxiety, despite a lack of guidance or approval from the FDA. This next wave of CBD regulations and companies will include large-scale clinical trials, the likes which have never been seen for this compound. Such trials are essential for patients and families who are desperate for new treatments and thus are now part of the CBD frenzy.

Dr. Yasmin Hurd, PhD, a groundbreaking researcher that has conducted clinical studies on CBD.

Dr. Yasmin Hurd, known for her work on CBD and opioid withdrawal at Mt. Sinai in New York, recently stated in an article,

“Another critical path toward greater evidenced-based research is the collaboration between legitimate companies and researchers that is important for developing appropriate medicinal formulations and routes of administration best suited for targeted medical indications.”

These collaborations can help address challenges such as the low bioavailability of CBD when taken orally due to extensive first-pass metabolism. Novel delivery and formulation strategies often require partnerships between industries.

Let us hope CBD can protect our brains and bodies from damage and stress, because a brutal, political and economic football match may be kicked off soon. The match will be between big pharma and an industry on the verge. The winners of this next phase of the CBD industry’s evolution will be the ones that have clearly invested in data and outcomes directly associated with their products. The major question, finally being asked, and that CBD companies are uniquely positioned to answer, is addressing the unsubstantiated hype around CBD, and being clear wherever there is actual, medicinal potential.